Browse News
Filter News
Found 294 articles
-
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023
3/7/2023
Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 28, 2023.
-
Arcturus Therapeutics to Attend Upcoming Investor Conferences
2/6/2023
Arcturus Therapeutics Holdings Inc. today announced that the Company will participate in the following investor conferences.
-
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
1/31/2023
Arcturus Therapeutics Holdings Inc. today announced that the Clinical Trial Application (CTA) for ARCT-032, an inhaled investigational mRNA medicine to treat cystic fibrosis (CF), received approval to proceed into a Phase 1 First-in-Human study in New Zealand.
-
JPM Day 3: Highlights
1/11/2023
Stay on top of what's happening at JPM. BioSpace is covering all the key announcements all week. -
mRNA Therapeutics Market Size To Hold USD 128.14 Bn By 2030
12/20/2022
The global mRNA therapeutics market size was exhibited at USD 48.1 billion in 2022 and it is expected to hold around USD 128.14 billion by 2030, growing at a CAGR of 13.03% from 2022 to 2030.
-
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/19/2022
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.
-
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
12/13/2022
Arcturus Therapeutics Holdings Inc. today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors.
-
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
12/12/2022
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics"; NASDAQ: ARCT).
-
Influenza Vaccine Market Size, Growth, Trends | Report 2022-2030
11/28/2022
The global influenza vaccine market was estimated at USD 7.02 billion in 2021 and it is expected to surpass around USD 15.13 billion by 2030, poised to grow at a CAGR of 8.91% from 2022 to 2030.
-
mRNA Therapeutics Market Worth USD 52.76 Billion By 2030 | CAGR: 4.7%
11/14/2022
Latest Study on “mRNA Therapeutics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.
-
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
11/9/2022
Scholar Rock today announced the appointment of Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer.
-
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
11/9/2022
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2022, and provided corporate updates.
-
Arcturus Therapeutics to Present at the Following Investor Conferences in November 2022
11/7/2022
Arcturus Therapeutics Holdings Inc., a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that the Company will present at the following investor conferences.
-
San Diego-based Arcturus Therapeutics signed a strategic collaboration and licensing deal with CSL Seqirus to help develop and commercialize vaccines.
-
Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
11/2/2022
At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health.
-
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
11/1/2022
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced a strategic collaboration with CSL Seqirus, a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines.
-
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
11/1/2022
CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc ("Arcturus Therapeutics") to access their late stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.
-
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
10/26/2022
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced that it will release its financial results for the quarter ended September 30, 2022 after the market close on Wednesday, November 9 and will also host a conference call and webcast at 4:30 pm Eastern Standard Time on November 9, 2022.
-
Arcturus Therapeutics to Attend the Following Investor Conferences
9/27/2022
Arcturus Therapeutics Holdings Inc. today announced that the Company will participate in the following investor conferences.
-
Rising Prevalence of Urea Cycle Disorders is Expected to Drive Urea Cycle Disorder Market Growth by 2030 - Reports and Data
9/26/2022
The latest market analysis report published by Reports and Data, titled ‘Global Urea Cycle Disorder Market – Forecast to 2030,’ thoroughly examines the Urea Cycle Disorder industry to provide essential data & information for the targeted readers.